Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.62 |
| ▸ | CA2 | P00918 | 7/20 | 0.62 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.51 |
| ▸ | BAD | Q92934 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | RARG | P13631 | 3/20 | 0.45 |
| ▸ | RXRA | P19793 | 3/20 | 0.45 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059895 | 0.84 | CA1 (0.66) | CA1CA2HRH3LMNAMAPT | |
| SCHEMBL11391436 | 0.78 | CA1 (0.63) | CA1CA2HRH3LMNACA12 | |
| SCHEMBL18812227 | 0.76 | CA1 (0.60) | CA1CA2HRH3LMNACA12 | |
| SCHEMBL16474744 | 0.76 | CA1 (0.60) | CA1CA2HRH3LMNAMAPT | |
| SCHEMBL1640794 | 0.73 | HRH3 (0.58) | HRH3NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11150434 | 0.72 | CA1 (0.55) | CA1CA2HRH3LMNAMAPT | |
| SCHEMBL11400808 | 0.71 | CA1 (0.54) | CA1CA2HRH3LMNAMAPT | |
| SCHEMBL13635446 | 0.71 | CA1 (0.54) | CA1CA2HRH3LMNAMAPT | |
| SCHEMBL29070695 | 0.71 | ADH5 (0.47) | MAPTRARGRXRAMEN1KMT2A | |
| SCHEMBL202110 | 0.71 | BCL2L1 (1.00) | CA1CA2BCL2L1BADLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2328586-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | Cephalon, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | CEPHALON, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| WO-2009142732-A2 | SUBSTITUTED PYRIDAZINONE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS | CEPHALON, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098269-A1 | Substituted Pyridazinone Derivatives as Histamine-3 (H3) Receptor Ligands | HRH3, HRH4, HRH2 | CA1 3303/4885CA2 2119/4885HRH3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.